IONIS PHARMACEUTICALS, INC.

(IONS)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
44.10 USD   +1.52%
08/10Citigroup Adjusts Ionis Pharmaceuticals' Price Target to $28 From $26, Maintains Sell Rating
MT
08/10Ionis reports second quarter financial results and recent business achievements
AQ
08/10RBC Cuts Price Target on Ionis Pharmaceuticals to $64 From $67, Maintains Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Promising hep B data helps GSK inch closer to functional cure

06/25/2022 | 09:00am EDT

LONDON, June 25 (Reuters) - An interim analysis of GSK’s experimental hepatitis B therapy bepirovirsen in a mid-stage study has raised hopes for a functional cure for millions suffering from a chronic infection, the British drugmaker said on Saturday.

If the results are reinforced in later-stage trials, the British drugmaker has estimated the drug could generate peak sales of more than 2 billion pounds ($2.5 billion) annually.

Although there are safe and effective vaccines for the hepatitis B virus - including shots made by GSK – nearly 300 million people globally have chronic hepatitis B (CHB), a long-lasting infection that occurs when the body is unable to fend off the virus and it persists in the blood and liver, according to the World Health Organization (WHO).

The mid-stage study is evaluating the impact of administering bepirovirsen in patients who were either on or off existing standard CHB therapy.

In the group of 227 patients on standard therapy, 24 weeks of treatment with bepirovirsen resulted in 28% of patients with sharp reductions in two key biomarkers of CHB such that a test would not be able to detect them.

Meanwhile, in the cohort of 230 patients who were not already on standard therapy, 24 weeks of treatment with bepirovirsen resulted in 29% of patients with corresponding decreases in the same biomarkers.

How durable these responses are remains to be seen.

Patients must be off therapy for typically six months or more and show no evidence of recurrence of the virus to achieve a functional cure, Christopher Corsico, GSK’s head of development, told Reuters.

But this data suggests that a functional cure is possible, Corsico said.

"The fact that you have such a high number of responses, just even when you stop the therapy is unprecedented ... compared to other drugs that are out there being tested."

Existing CHB medicines, such as nucleoside/nucleotide analogues (NA), are often taken for life because they suppress but rarely clear the virus. Despite their use, patients can develop serious complications, including liver cancer. In 2019, hepatitis B resulted in some 820,000 deaths, according to WHO estimates.

GSK, led by CEO Emma Walmsley, licensed bepirovirsen from Ionis Pharmaceuticals in 2019. The drug is designed to combat the disease on three fronts: by inhibiting viral replication, by suppressing the production of viral proteins associated with hepatitis B virus infection, and by stimulating the immune system.

($1 = 0.8155 pounds) (Reporting by Natalie Grover in London; Editing by David Holmes)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
GSK PLC 3.57% 1450 Delayed Quote.-11.78%
IONIS PHARMACEUTICALS, INC. 1.52% 44.1 Delayed Quote.42.75%
All news about IONIS PHARMACEUTICALS, INC.
08/10Citigroup Adjusts Ionis Pharmaceuticals' Price Target to $28 From $26, Maintains Sell R..
MT
08/10Ionis reports second quarter financial results and recent business achievements
AQ
08/10RBC Cuts Price Target on Ionis Pharmaceuticals to $64 From $67, Maintains Outperform Ra..
MT
08/09IONIS PHARMACEUTICALS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
08/09IONIS PHARMACEUTICALS : 2Q22 Earnings Slides
PU
08/09IONIS PHARMACEUTICALS : reports second quarter financial results and recent business achie..
PU
08/09TRANSCRIPT : Ionis Pharmaceuticals, Inc., Q2 2022 Earnings Call, Aug 09, 2022
CI
08/09Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022
CI
08/09Ionis Pharmaceuticals Reports Higher Q2 Revenue, Wider Loss
MT
08/09IONIS PHARMACEUTICALS : Q2 Earnings Snapshot
AQ
More news
Analyst Recommendations on IONIS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 593 M - -
Net income 2022 -383 M - -
Net cash 2022 797 M - -
P/E ratio 2022 -16,3x
Yield 2022 -
Capitalization 6 260 M 6 260 M -
EV / Sales 2022 9,21x
EV / Sales 2023 8,93x
Nbr of Employees 660
Free-Float 99,3%
Chart IONIS PHARMACEUTICALS, INC.
Duration : Period :
Ionis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IONIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 44,10 $
Average target price 49,61 $
Spread / Average Target 12,5%
EPS Revisions
Managers and Directors
Brett P. Monia Chief Executive Officer & Director
Elizabeth L. Hougen Chief Accounting Officer
Joseph Loscalzo Chairman
C. Frank Bennett Chief Scientific Officer & Executive VP
Sanjay Bhanot Chief Medical Officer & SVP
Sector and Competitors
1st jan.Capi. (M$)
IONIS PHARMACEUTICALS, INC.42.75%6 260
MODERNA, INC.-32.60%66 966
IQVIA HOLDINGS INC.-12.88%45 846
LONZA GROUP AG-25.13%44 851
SEAGEN INC.10.05%31 380
ALNYLAM PHARMACEUTICALS, INC.37.90%28 068